Also combo Clin1 head & neck cancer (partner: Merck), Clin1 oropharyngeal cancer; CUE-102 Clin1 solid tumors (partner: LG Chem); CUE-103 Clin0 immuno-oncology; Neo-STAT Clin0 immuno-oncology; RDI-STAT Clin0 immuno-oncology
CueBiopharma is developing immunotherapies to create a new class of cancer therapeutics. Within the body the immune system gets activated in response to molecules cues. CueBiopharma is creating therapeutics that mimic these natural cues of the immune system and activate tumor-specific T cells within the patient to attack only cancer cells. Advantages of this approach include improved safety and a more effective response as it restores the capacity of the patient’s own immune system. CueBiopharma’s lead candidate, CUE-101, works by mimicking the molecule IL-2 and activating a specific population of T-cells and is being tested currently in Phase 1 clinical trials.